Goldman Sachs
ODT

Goldman Sachs’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Goldman Sachs’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-58,210
Closed -$79K – 7183
2021
Q4 		$79K Buy
58,210
+12,050
+26% +$28.5K ﹤0.01% 6185
2021
Q3 		$134K Sell
46,160
-47,658
-51% -$158K ﹤0.01% 5850
2021
Q2 		$327K Buy
93,818
+20,581
+28% +$70.7K ﹤0.01% 5472
2021
Q1 		$251K Sell
73,237
-10,119
-12% -$191K ﹤0.01% 5526
2020
Q4 		$1.6M Sell
83,356
-3,259
-4% -$50.3K ﹤0.01% 3888
2020
Q3 		$1.16M Buy
86,615
+59,126
+215% +$1.67M ﹤0.01% 3969
2020
Q2 		$1.16M Buy
27,489
+16,537
+151% +$535K ﹤0.01% 3851
2020
Q1 		$302K Sell
10,952
-11,928
-52% -$348K ﹤0.01% 4496
2019
Q4 		$743K Sell
22,880
-25,392
-53% -$787K ﹤0.01% 4298
2019
Q3 		$1.26M Buy
48,272
+41,183
+581% +$1.38M ﹤0.01% 3879
2019
Q2 		$260K Sell
7,089
-3,682
-34% -$88.2K ﹤0.01% 4676
2019
Q1 		$238K Buy
+10,771
New +$188K ﹤0.01% 4730
2018
Q4 		– Sell
-16,701
Closed -$324K – 5836
2018
Q3 		$324K Buy
+16,701
New +$341K ﹤0.01% 4681
2018
Q2 		– Sell
-31,871
Closed -$675K – 6148
2018
Q1 		$675K Buy
31,871
+5,491
+21% +$129K ﹤0.01% 4295
2017
Q4 		$660K Buy
+26,380
New +$623K ﹤0.01% 4611

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Goldman Sachs's ODT Position: Q1 2022 in Review

Goldman Sachs sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 58,210 shares — an estimated $79K sold.

Goldman Sachs first reported a position in ODT in Q4 2017 and held it in 15 quarters. The position peaked at $1.6M in Q4 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Goldman Sachs reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Goldman Sachs sold 58,210 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $79K.
  • Goldman Sachs first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 15 quarters.
  • Goldman Sachs's Odonate Therapeutics, Inc. Common Stock position peaked at $1.6M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.